William Cavanagh III

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About William Cavanagh III

Perspective Therapeutics, Inc. reported in an 8-K filed February 10, 2023 that William Cavanagh III was terminated as Chief Research and Development Officer, effective February 7, 2023.

“William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.”

Perspective Therapeutics, Inc. Form 8-K, filed February 10, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize William Cavanagh III's recent executive appointments or departures and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Perspective Therapeutics, Inc. (CATX)
Proxy statement

Start not stated–2023-02-07

Company network

Recorded roles and call appearances connecting this person to public companies.

Perspective Therapeutics, Inc.

CATX

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Executive change Terminated: Chief Research and Development Officer Perspective Therapeutics, Inc. (CATX)
2023-02-07